Both Merck & Co. Inc.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb Co.’s Opdivo (nivolumab) were approved by the FDA to treat advanced metastatic melanoma last year, but that’s only the start of the possibilities for the PD-1 pathway drugs. (See BioWorld Today, Sept. 5, 2014.)